1. Home
  2. LTRX vs IKT Comparison

LTRX vs IKT Comparison

Compare LTRX & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantronix Inc.

LTRX

Lantronix Inc.

HOLD

Current Price

$6.89

Market Cap

225.9M

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.68

Market Cap

201.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTRX
IKT
Founded
1989
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
225.9M
201.3M
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
LTRX
IKT
Price
$6.89
$1.68
Analyst Decision
Strong Buy
Buy
Analyst Count
3
3
Target Price
$6.17
$6.00
AVG Volume (30 Days)
584.8K
647.5K
Earning Date
02-05-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$118,294,000.00
N/A
Revenue This Year
$4.59
N/A
Revenue Next Year
$12.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$1.33
52 Week High
$6.96
$3.32

Technical Indicators

Market Signals
Indicator
LTRX
IKT
Relative Strength Index (RSI) 72.98 46.51
Support Level $5.94 $1.63
Resistance Level $6.63 $1.73
Average True Range (ATR) 0.38 0.14
MACD 0.07 -0.04
Stochastic Oscillator 98.07 8.50

Price Performance

Historical Comparison
LTRX
IKT

About LTRX Lantronix Inc.

Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: